New drug shows promise for kidney disease in early trial
NCT ID NCT04287985
First seen May 02, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tested a new medicine called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers tracked side effects and urine protein levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Visterra Investigational Site
Birmingham, Alabama, 35294, United States
-
Visterra Investigational Site
Los Angeles, California, 90027, United States
-
Visterra Investigational Site
Oxnard, California, 93036, United States
-
Visterra Investigational Site
Palo Alto, California, 94305, United States
-
Visterra Investigational Site
Stanford, California, 94305, United States
-
Visterra Investigational Site
Denver, Colorado, 80230, United States
-
Visterra Investigational Site
Lawrenceville, Georgia, 30046, United States
-
Visterra Investigational Site
Baton Rouge, Louisiana, 70808, United States
-
Visterra Investigational Site
New Orleans, Louisiana, 70121, United States
-
Visterra Investigational Site
Baltimore, Maryland, 21201, United States
-
Visterra Investigational Site
Tupelo, Mississippi, 38801, United States
-
Visterra Investigational Site
New York, New York, 10016, United States
-
Visterra Investigational Site
Chapel Hill, North Carolina, 27599, United States
-
Visterra Investigational Site
Columbus, Ohio, 43210, United States
-
Visterra Investigational Site
Bethlehem, Pennsylvania, 18017, United States
-
Visterra Investigational Site
Houston, Texas, 77030, United States
-
Visterra Investigational Site
Houston, Texas, 77054, United States
-
Visterra Investigational Site
New Lambton Heights, New South Wales, 2305, Australia
-
Visterra Investigational Site
Saint Leonards, New South Wales, 2065, Australia
-
Visterra Investigational Site
Nambour, Queensland, 4560, Australia
-
Visterra Investigational Site
Nedlands, Western Australia, 6009, Australia
-
Visterra Investigational Site
Calgary, Alberta, T2N 2T9, Canada
-
Visterra Investigational Site
Brampton, Ontario, L6R 3J7, Canada
-
Visterra Investigational Site
Montreal, Quebec, H4A 3J1, Canada
-
Visterra Investigational Site
Hong Kong, HK, Hong Kong
-
Visterra Investigational Site
Hong Kong, Hong Kong
-
Visterra Investigational Site
Kowloon, 999077, Hong Kong
-
Visterra Investigational Site
Tsuen Wan, Hong Kong
-
Visterra Investigational Site
Chandigarh, Chandigarh, 160012, India
-
Visterra Investigational Site
Bangalore, Karnataka, 560054, India
-
Visterra Investigational Site
Bengaluru, Karnataka, 560034, India
-
Visterra Investigational Site
Manipal, Karnataka, 576104, India
-
Visterra Investigational Site
Kozhikode, Kerala, 673008, India
-
Visterra Investigational Site
Thiruvananthapuram, Kerala, 695011, India
-
Visterra Investigational Site
New Delhi, National Capital Territory of Delhi, 110060, India
-
Visterra Investigational Site
Vellore, Tamil Nadu, 632004, India
-
Visterra Investigational Site
Hyderabad, Telangana, 500012, India
-
Visterra Investigational Site
Hyderabad, Telangana, 500082, India
-
Visterra Investigational Site
Raebareli, Uttar Pradesh, 226014, India
-
Visterra Investigational Site
Toyoake-shi, Aichi-ken, 470-1192, Japan
-
Visterra Investigational Site
Tokyo, Nerima Ku, 177-8521, Japan
-
Visterra Investigational Site
Ashikaga, Tochigi, 326-0843, Japan
-
Visterra Investigational Site
Ashikaga-Shi, 326-0843, Japan
-
Visterra Investigational Site
Bunkyō City, 113-8431, Japan
-
Visterra Investigational Site
Kashihara-shi, 634-8522, Japan
-
Visterra Investigational Site
Minatoku, 470-1192, Japan
-
Visterra Investigational Site
Niigata, 951-8520, Japan
-
Visterra Investigational Site
Shinjuku-Ku, 162-8666, Japan
-
Visterra Investigational Site
Tsukuba, 305-876, Japan
-
Visterra Investigational Site
Urayasu-Shi, 279-0021, Japan
-
Visterra Investigational Site
Klang, 41200, Malaysia
-
Visterra Investigational Site
Kuala Lumpur, 56000, Malaysia
-
Visterra Investigational Site
Kuala Lumpur, 59100, Malaysia
-
Visterra Investigational Site
Kuantan, 25100, Malaysia
-
Visterra Investigational Site
Seremban, 70300, Malaysia
-
Visterra Investigational Site
Diliman, 1101, Philippines
-
Visterra Investigational Site
Quezon City, 1102, Philippines
-
Visterra Investigational Site
Singapore, 169608, Singapore
-
Visterra Investigational Site
Singapore, 308433, Singapore
-
Visterra Investigational Site
Seoul, Dongdaemun-gu, 130-872, South Korea
-
Visterra Investigational Site
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Visterra Investigational Site
Anyang, 431-070, South Korea
-
Visterra Investigational Site
Gangdong, 5355, South Korea
-
Visterra Investigational Site
Hwaseong-si, 18450, South Korea
-
Visterra Investigational Site
Seongnam-si, 13620, South Korea
-
Visterra Investigational Site
Seoul, 05030, South Korea
-
Visterra Investigational Site
Seoul, 3080, South Korea
-
Visterra Investigational Site
Seoul, 3722, South Korea
-
Visterra Investigational Site
L'Hospitalet de Llobregat, B, 8907, Spain
-
Visterra Investigational Site
Santander, CB, 39010, Spain
-
Visterra Investigational Site
Córdoba, CO, 14004, Spain
-
Visterra Investigational Site
Seville, SE, 41009, Spain
-
Visterra Investigational Site
Barcelona, 8025, Spain
-
Visterra Investigational Site
Madrid, 28034, Spain
-
Visterra Investigational Site
Seville, 41013, Spain
-
Visterra Investigational Site
Valencia, 46017, Spain
-
Visterra Investigational Site
Colombo, 800, Sri Lanka
-
Visterra Investigational Site
Kandy, 20000, Sri Lanka
-
Visterra Investigational Site
Nugegoda, Sri Lanka
-
Visterra Investigational Site
Kaohsiung City, 82445, Taiwan
-
Visterra Investigational Site
Kaohsiung City, 83301, Taiwan
-
Visterra Investigational Site
Keelung, 20104, Taiwan
-
Visterra Investigational Site
New Taipei City, 23142, Taiwan
-
Visterra Investigational Site
New Taipei City, 23561, Taiwan
-
Visterra Investigational Site
Xitun, 40705, Taiwan
-
Visterra Investigational Site
Bangkok, 10310, Thailand
-
Visterra Investigational Site
Chiang Mai, 50200, Thailand
-
Visterra Investigational Site
Ratchathewi, 10400, Thailand
-
Visterra Investigational Site
Bradford, BD5 0NA, United Kingdom
-
Visterra Investigational Site
London, E11BB, United Kingdom
-
Visterra Investigational Site
London, SE5 9RS, United Kingdom
-
Visterra Investigational Site
London, W12 0HS, United Kingdom
-
Visterra Investigational Site
Salford, M6 8HD, United Kingdom
Conditions
Explore the condition pages connected to this study.